Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab and Tislelizumab in PD1-high/low tumors
NCT04802876Phase 2Active, not recruiting
- Sponsor
- SOLTI
- Start
- Apr 2021
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab, tislelizumab in solid tumor, sponsored by SOLTI. Started Apr 2021; status: active, not recruiting.
02
Drugs
spartalizumabtislelizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04802876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802876.